Lakefront Biotherapeutics (LKFT) EBT (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported EBT for 13 consecutive years, with $15.9 million the latest figure, recorded in Q1 2026.

• Quarterly EBT rose 108.93% year-over-year to $15.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $536.2 million (up 358.35% YoY) and the FY2025 annual result came in at $342.4 million, up 9852.71% from the prior year.
• EBT retreated to $15.9 million in Q1 2026 per LKFT's latest filing, from $891.2 million in the prior quarter.
• Over the last five years, EBT for LKFT reached as high as $891.2 million in Q4 2025 and fell as low as -$549.3 million in Q3 2025.
• A 5-year average of $2.8 million and a median of -$15.4 million in 2023 frame the typical range for EBT.
• Annual changes were most pronounced in 2022 — EBT sank 1631.8% — and 2025, when it jumped 4015.15%.
• Year by year, EBT stood at -$72.0 million in 2022, then surged by 32.46% to -$48.6 million in 2023, then soared by 144.52% to $21.7 million in 2024, then jumped by 4015.15% to $891.2 million in 2025, then slumped by 98.22% to $15.9 million in 2026.
• According to Business Quant data, EBT over the past three periods registered $15.9 million, $891.2 million, and -$549.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.